Objective To compare the effect of coronary revascularization between titanium nitric-oxide biological availability stent (Titan2-BAS) and sirolimus-eluting stent (SES) in elderly patients. Methods One hundred and twenty-five patients with coronary artery diseases were enrolled,including 75 males and 50 females. The patients were categorized into Titan2-BAS group (group A,n=79) and SES group (n=46). All the stents were implanted through transulnar or transradial approach. Patients in group A received aspirin and clopidogrel for 1 to 3 months,while patients in group B received the same medications for at least 12 months. The success rate of stent implantation,incidence of in-stent thrombosis in early period and incidence of major adverse cardiac events(MACE)during follow-up visit,including death,acute myocardial infarction,and criminal artery reestablishment were observed in both groups. Results (1) The lesion was averagely (25±3.6) mm long and (3.1±0.3) mm internal diameter in group A,and (24±4.2) mm long and (3.1±0.4) mm internal diameter in group B,with no significant difference between the two groups. (2) In group A,146 Titan2-BAS were implanted in 129 narrowed lesions,and 1 stent implantation failed. In group B,82 SES were implanted in 72 lesions. The success rate of stent implantation were 99.3% in group A and 100% in group B,with no significant difference between the two groups. (3) All subjects survived,and were followed up for 1-17 months (average 5.8 months). One patient presented in-stent thrombosis on the second day after stent implantation in group B,whereas no thrombosis developed in group A. One patient was submitted to revascularization in the third month after stent implantation in group A,while no revascularization was performed in group B. In general,there was no difference between group A and B in the incidence of MACE(1.3% vs 2.2%). Conclusion Concerning coronary revascularization,the short and long-term efficacy of Titan2-BAS is similar to that of SES in elderly patients with coronary artery disease. Titan2-BAS adds no extra risk of MACE.?更多